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Nutritional status may have a profound impact on the pharmacokinetics of drugs, yet only few data are available for tuberculosis
(TB) drugs. As malnutrition occurs frequently among TB patients, we assessed the effect of malnutrition on the steady-state
pharmacokinetics of total and protein-unbound rifampin during the intensive phase of TB treatment. In a descriptive pharma-
cokinetic study in Bandung, Indonesia, patients received a fixed standard rifampin dose of 450 mg once daily during the inten-
sive phase of TB treatment. A full pharmacokinetic curve for rifampin was recorded, and total and unbound concentrations of
rifampin were analyzed in all samples. Rifampin pharmacokinetic parameters were compared between severely malnourished
(BMI of<16.0 kg/m2), malnourished (BMI of<18.5 kg/m2), and well-nourished (BMI of >18.5 kg/m2) individuals. No differ-
ence in total and protein-unbound pharmacokinetic parameters between severely malnourished (n 7), malnourished (n 11),
and well-nourished (n 25) patients could be demonstrated. In addition, no significant correlation between BMI and exposure
(area under the concentration-time curve from 0 to 24 h [AUC0–24] andmaximum concentration of drug in serum [Cmax]) was
found. Females had significantly higher total AUC0–24 (geometric mean, 59.2 versus 48.2 h · mg/liter; P 0.02) and higher un-
bound AUC0–24 (geometric mean, 6.2 versus 4.8 h · mg/liter; P 0.02) thanmales. Overall, a marked 2-fold interindividual vari-
ation in the free fraction was observed (7.6 to 15.0%; n 36). Nutritional status and BMI do not appear to have a major effect on
total and protein-unbound pharmacokinetic parameters of rifampin in Indonesian subjects. The large interindividual variability
in the free fraction of rifampin suggests that protein-unbound rather than total rifampin concentrations should preferably be
used to study exposure-response relationships.
Inadequate exposure to rifampin and other antituberculosis (an-ti-TB) drugs may contribute to a suboptimal clinical response
in anti-TB treatment. This follows from a recent study per-
formed in a preclinical model, showing that pharmacokinetic
variability is an important factor in the emergence of multi-
drug-resistant TB (1). Furthermore, a meta-analysis of clinical
studies showed that pharmacokinetic variability for a single
drug (isoniazid) in multidrug TB regimens is associated with
therapy failure and acquired drug resistance (2). A number of
clinical studies have also reported associations between low
concentrations of anti-TB drugs and poor treatment response
(3–8), but this association was not found in other studies (9,
10), including one of our studies on plasma rifampin concen-
trations in Indonesian TB patients (11).
For rifampin and other TB drugs, pharmacokinetic variability
and low exposure may be affected by various factors, including
gender, comorbidity (HIV/AIDS or diabetes mellitus), genetics,
drug formulation, and malnutrition (3, 12–16). Malnutrition oc-
curs frequently among TB patients. A case (n 121)-control (n
371) study in Indonesia documented malnutrition in 87% and
33% of cases and controls, respectively (17). A bidirectional inter-
action exists between malnutrition and TB (18, 19). On the one
hand, malnutrition impairs immune function and increases the
susceptibility to development of active TB. At the same time, TB
leads to severe abnormalities in protein metabolism and loss of
lean tissues and fat reserves. It is known that nutritional status can
have a profound impact on the pharmacokinetics of drugs (20,
21), yet few data are available for TB drugs, and we are aware of
only one publication on the effect of malnutrition on the exposure
to rifampin (12).
In pharmacokinetic studies, measurement of rifampin concen-
trations in plasma or serum usually relates to the total (protein-
unbound plus protein-bound) concentration of a drug. An equi-
librium between total and protein-unbound concentrations is
commonly assumed, yet free rather than total drug concentrations
are preferably used in concentration-response evaluations (22), as
only protein-unbound drugs are pharmacologically active and
diffuse or are being actively transported into tissues and to the
sites of action (23, 24). In a previous study among Indonesian TB
patients (11), we confined measurements to total concentrations
of rifampin, and this may be one of several possible explanations
for the absence of a concentration-response relationship in that
study. Importantly, malnutrition and associated low concentra-
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tions of drug-binding plasma proteins may cause a change in the
equilibrium between protein-unbound and -bound concentra-
tions, which renders the total drug concentrations misleading
(24–26). This means that both total and protein-unbound plasma
concentrations should be evaluated when studying the effects of
malnutrition on the pharmacokinetics of a drug.
The primary objective of this study was to assess the effect of
malnutrition on the steady-state pharmacokinetics of total and
protein-unbound rifampin during the intensive phase of TB treat-
ment in Indonesian TB patients. As a secondary objective, we
evaluated the interindividual variability in exposure to protein-
unbound rifampin, as we feel this may provide relevant informa-
tion to understand exposure-response relationships for this piv-
otal TB drug.
MATERIALS AND METHODS
Subjects. Study subjects were Indonesian patients with pulmonary TB in
the intensive phase of treatment. Diagnosis of pulmonary TB was based
on clinical symptoms and chest X-ray examination, confirmed by micro-
scopic detection of acid-fast bacilli. Patients were excluded if they had a
body weight (BW) above 55 kg, were below 18 or above 55 years of age,
were pregnant or lactating, used any type of comedication that may influ-
ence the pharmacokinetics of TB drugs, or had liver or kidney abnormal-
ities (including abnormal liver or renal function parameters) or any
known history or medical condition that might affect the pharmacokinet-
ics of TB drugs, such as diabetes mellitus, HIV infection, diarrhea, or
vomiting.
Study design. This was a descriptive pharmacokinetic study con-
ducted in an urban outpatient tuberculosis clinic in Bandung, Indonesia.
Patients were prospectively and consecutively recruited from the control
arm of an intervention study on nutritional supplementation in TB pa-
tients. Subsequently, the cohort was completed with data from patients
who participated in a clinical trial on high-dose rifampin and who fulfilled
the inclusion and exclusion criteria (27). During the intensive phase of TB
treatment, all eligible patients received a fixed standard rifampin dose of
450 mg once daily, roughly corresponding to 10 mg/kg in Indonesian
people (for people below 55 kg), combined with once-daily isoniazid (300
mg), pyrazinamide (1,500 mg), and ethambutol (750 mg). All patients
received TB drugs from the same manufacturer (PT Kimia Farma, Band-
ung, Indonesia), formulated in separate tablets. The bioequivalence of the
rifampin tablets and an international reference standard has been estab-
lished before (28).
A full pharmacokinetic curve for rifampin was recorded between 2 and
6 weeks after the start of TB treatment, when steady state for the TB drugs
can be expected (29). Body weight and height (to calculate body mass
index [BMI]) and concomitant drug use were also assessed at the phar-
macokinetic sampling day. In addition, plasma protein albumin was mea-
sured, considering that 30 to 41% of protein-bound rifampin is associated
with the serum albumin fraction (30). Informed consent was obtained
from all subjects, and the study was approved by the Independent Ethics
Committee, Faculty of Medicine, University of Padjadjaran, Bandung,
Indonesia.
Blood sampling, bioanalysis, and pharmacokinetic data analysis.
Patients refrained from the intake of any food or any drugs (other than
study medication) starting from 11:00 p.m. on the day preceding the
pharmacokinetic assessment until 4 h after the intake of study medication.
TB drugs were taken with 230 ml of still water. Serial blood samples (10
ml) were collected from the antecubital vein just before and at 0.5, 1, 1.5,
2, 2.5, 3, 4, 6, 8, and 12 h after observed TB drug intake. Plasma was
immediately separated, frozen at20°C, and transferred to80°C within
72 h until transport on dry ice to The Netherlands for bioanalysis.
Bioanalysis. The total (protein-bound plus -unbound) plasma con-
centrations of rifampin were determined with a validated high-perfor-
mance liquid chromatographic (HPLC) method with UV detection as
described previously (27). The lower limit of quantitation for this method
was 0.28 mg/liter.
In addition to total plasma concentrations, protein-unbound concen-
trations of rifampin were measured in all obtained samples. Measure-
ments were based on ultrafiltration to separate bound from unbound
rifampin, followed by HPLC. Briefly, 0.5 ml of plasma was added into
a Centrifree YM-30 tube (Millipore, Amsterdam, The Netherlands).
Plasma was centrifuged for 15 min at 1,650 g at 25°C with a Rotanta 46
R, rotor 4445 (radius 164, 45°). The clear ultrafiltrate was placed in a
thermostated autosampler (4°C), and 50l of this solution was injected in
the HPLC system. The analytical column was an OmniSpher 5 C18 col-
umn (250 by 4.6 mm [inner diameter]; particle size, 5m) protected by a
Chromguard RP ss 10- by 3-mm column (Varian, Middelburg, The Neth-
erlands). The mobile-phase components were 30% acetonitrile and 70%
10 mM phosphate buffer (pH 5), run during a HPLC gradient with dif-
ferent flow rates. The total run time was 17 min. UV detection was set at
334 nm. The average accuracy of ultrafiltrate spiked with rifampin was
107%. Intraday imprecision in measurement of rifampin in ultrafiltrate
varied from 1.4 to 2.4%, interday imprecision varied from 0% (i.e., there
was no additional variation upon intraday imprecision as a result of per-
forming the assay on different days) to 3.6%, and overall precision varied
from 1.4 to 3.9%, depending on the concentration measured. The range of
the method for unbound rifampin plasma concentrations was from 0.06
mg/liter (limit of quantitation) to 13 mg/liter.
Pharmacokinetic analysis. Pharmacokinetic parameters were as-
sessed using standard noncompartmental methods in WinNonLin
version 5.3 (Pharsight Corporation) as described before (27). Unbound
fractions were calculated by dividing the unbound area under the concen-
tration-time curve from 0 to 24 h (AUC0 –24) by the total AUC0 –24 for all
study subjects.
Statistical analysis. Based on available data for the pharmacokinetics
of rifampin in Indonesian patients (27), it was calculated that a minimum
of 15 patients per group were required to detect a difference of 25% in the
AUC0 –24 of total rifampin with a significance level of 0.05 and a power of
80% (two-sided test).
Patients were first divided into three subgroups based on criteria for
nutritional status as proposed by the World Health Organization (31).
Patients with a BMI of 16.0 kg/m2 were considered severely malnour-
ished, patients with a BMI of 18.5 kg/m2 were regarded as malnour-
ished, and patients with a BMI of18.5 kg/m2 were considered to have no
malnutrition. Differences in pharmacokinetic parameters between mal-
nourished patients as well as the severely malnourished subgroup versus
well-nourished patients were assessed with independent-sample t tests on
logarithmically transformed pharmacokinetic parameters. Time to max-
imum concentration of drug in serum (Tmax) values were not trans-
formed and were compared using the Mann-Whitney U test. Apart from
categorizing patients in groups with predefined BMI values, BMI was also
evaluated as a continuous variable. AUC0 –24 and maximum concentra-
tion of drug in serum (Cmax) values for both total and unbound rifampin
plasma concentrations were correlated with BMI using Spearman’s rho
on the untransformed pharmacokinetic parameters.
To evaluate the confounding effect of other possible determinants of
exposure to protein-unbound and total rifampin, similar univariate anal-
yses were performed to assess the effects of gender, weight, age, and
plasma albumin concentration on the log-transformed AUC0 –24 and
Cmax values for the total and unbound concentrations of rifampin. After
the univariate analyses, a multiple linear regression analysis was per-
formed to assess the variation in log-transformed AUC0 –24 and Cmax at-
tributable to the presence of those variables that emerged from the uni-
variate analyses.
To assess the interindividual variability in pharmacokinetics as a sec-
ondary objective, all patients were combined in one group. First, the cen-
tral tendency and spread in each pharmacokinetic parameter (protein-
unbound and total rifampin) were described with a geometric mean,
geometric coefficient of variation (GCV) (standard deviation [SD] of ln-
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transformed data 100%), and range, apart from Tmax, which was pre-
sented as median and range. The variability in average (arithmetic mean)
percent unbound rifampin (unbound AUC0 –24/total AUC0 –24) was de-
scribed with a coefficient of variation (CV) (SD/mean  100%) deter-
mined over all individual pharmacokinetic curves. Second, the geometric
mean total and protein-unbound plasma concentrations and average ra-
tios of unbound to total rifampin were calculated for all individual sam-
ples at each sampling time point.
All statistical evaluations were performed with SPSS for Windows ver-
sion 16.0 (SPSS Inc., Chicago, IL). P values of less than 0.05 were consid-
ered statistically significant in all analyses.
RESULTS
Patients. Thirty-six patients with pulmonary TB were included in
the study. Characteristics of the patients are presented in Table 1.
The majority of the patients were female (61%). Twenty-five pa-
tients had a normal BMI (BMI of 18.5 kg/m2), and 11 patients
were malnourished (BMI of 18.5 kg/m2), of which seven pa-
tients were severely malnourished (BMI of 16.0 kg/m2). As all
patients received a fixed dose of 450 mg of rifampin; the dosage of
rifampin per kilogram of body weight was somewhat higher
among malnourished patients than among those with a normal
BMI (11.6 mg/kg BW versus 9.7 mg/kg BW [geometric mean]).
Albumin concentrations were within the normal range for se-
verely malnourished, malnourished, and well-nourished patients:
3.3, 3.4, and 3.8 g/dl (geometric mean), respectively. Albumin
concentrations in severely malnourished and malnourished pa-
tients did not differ significantly from those in well-nourished
patients (P 0.12 and P 0.19, respectively).
Effect of malnutrition on the pharmacokinetics of rifampin.
The geometric mean AUC0 –24 of rifampin did not differ between
patients with malnutrition (BMI of 18.5 kg/m2) and patients
with a normal BMI, for both the total AUC0–24 (54.8 versus 54.6 h ·
mg/liter; P 0.96) and the unbound plasma AUC0 –24 (5.7 versus
5.6 h · mg/liter; P 0.95) (Table 2). Total and unbound geometric
mean Cmax and other rifampin pharmacokinetic parameters, es-
pecially the primary parameters clearance and volume of distribu-
tion, also were similar in the two nutrition groups (Table 2). Se-
verely malnourished patients (BMI of 16.0 kg/m2) showed no
differences in AUC0 –24 compared to patients with a normal BMI
either; geometric mean values for total and protein-unbound
AUC0 –24 were 56.7 and 6.1 h · mg/liter, respectively, among se-
verely malnourished patients, compared to 54.6 and 5.6 h · mg/
liter, respectively, for patients with a normal BMI (P  0.73 and
0.53, respectively). Evaluation of Cmax values yielded similar re-
sults; geometric mean values for total and protein-unbound Cmax
were 10.7 and 1.0 mg/liter, respectively, among severely malnour-
ished patients, compared to 10.9 and 1.1 mg/liter, respectively, in
patients with a normal BMI (P 0.91 and P 0.65, respectively).
TABLE 1 Demographic, clinical, and laboratory characteristics of the
study population
Characteristic Value (n 36)a
Age (yr) 35 (18–55)
Male sex (%) 39
Wt (kg) 44 (34–53)
BMI (kg/m2) 19.0 (13.5–22.6)
Severely malnourished (BMI,16 kg/m2; n 7) 15.3 (13.5–15.8)
Malnourished (BMI, 16–18.49 kg/m2; n 4) 16.3 (16.1–16.4)
Normal BMI (BMI,18.5 kg/m2; n 25) 19.6 (18.7–22.6)
Albumin (g/dl) 3.8 (2.6–4.2)
Hemoglobin (g/dl) 11.7 (8.9–14.4)
Rifampin dose (mg/kg) 10.3 (8.5–13.2)
Severely malnourished (BMI,16 kg/m2; n 7) 12.4 (10.5–13.2)
Malnourished (BMI, 16–18.49 kg/m2; n 4) 11.4 (10.5–13.2)
Normal BMI (BMI,18.5 kg/m2; n 25) 9.6 (8.5–11.5)
a Data are presented as median (minimum–maximum) unless stated otherwise.
TABLE 2 Steady-state pharmacokinetics of total and unbound rifampin based on full pharmacokinetic curves of the total cohort
Parameter in plasmaa
Value for groupb
P valueTotal (n 36) BMI 18.5 (n 11) BMI 18.5 (n 25)
Total rifampin
AUC0–24 (h · mg/liter) 54.7 (32.6–88.8) 54.8 (32.6–85.0) 54.6 (35.0–88.8) 0.96
d
Cmax (mg/liter) 10.9 (6.4–16.6) 10.9 (6.4–16.6) 10.9 (7.1–16.3) 0.95
d
Tmax (h) (median) 2.0 (1.0–4.0) 2.5 (1.0–4.0) 1.5 (1.0–4.0) 0.17
e
CL/F (liters/h) 8.2 (5.1–13.8) 8.2 (5.3–13.8) 8.2 (5.1–12.9) 0.96d
V/F (liters) 24.1 (15.1–57.4) 25.1 (16.6–36.0) 23.7 (15.1–57.4) 0.63d
Half-life (h) 2.0 (1.4–3.8) 2.1 (1.4–2.8) 2.0 (1.5–3.8) 0.47d
Unbound rifampin
AUC0–24 (h · mg/liter) 5.6 (2.9–9.8) 5.7 (2.9–8.7) 5.6 (3.2–9.8) 0.95
d
Cmax (mg/liter) 1.1 (0.7–2.2) 1.0 (0.7–2.0) 1.1 (0.7–2.2) 0.45
e
Tmax (h) (median) 2.0 (1.0–4.0) 2.5 (1.0–4.0) 1.5 (1.0–4.0) 0.06
d
CL/F (liters/h) 79.8 (45.9–156) 79.3 (51.9–156) 80.0 (45.9–142) 0.95d
V/F (liters) 320 (107–741) 337 (161–654) 313 (108–747) 0.65d
Half-life (h) 2.8 (1.2–6.8) 2.9 (2.0–4.0) 2.7 (1.2–6.8) 0.52d
Unbound fraction
AUC ratio (%) (avg)c 10.5 (7.6–15.0) 10.5 (8.9–14.9) 10.5 (7.6–15.0) 0.99d
a CL, clearance; V, volume of distribution.
b Data are presented as geometric mean (minimum–maximum) unless stated otherwise.
c The AUC ratio was calculated by dividing unbound AUC0 –24 by total AUC0 –24 in all subjects.
d By independent-sample t test on log-transformed pharmacokinetic parameters between malnourished and well-nourished patients.
e By Mann-Whitney U test between malnourished and well-nourished patients.
Malnutrition and Rifampin
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Since patients who were severely malnourished or malnourished
had a lower body weight while receiving the same fixed 450-mg
dose of rifampin, a similar AUC0 –24 is explained by a trend toward
a higher clearance per kilogram in both severely malnourished
[0.21 liter/(h · kg)] and malnourished [0.21 liter/(h · kg)] patients
versus well-nourished patients [0.18 liter/(h · kg)] (P 0.09 and
P 0.07, respectively).
Apart from categorizing patients in groups with predefined
BMI values, BMI was also evaluated as a continuous variable.
There was no significant correlation between BMI and AUC0 –24
for both total and unbound rifampin plasma concentrations
(Spearman’s rho, 0.035 and 0.055, respectively; P  0.84 and
P  0.75, respectively), nor was there a significant correlation
between BMI and Cmax for total and unbound rifampin plasma
levels (Spearman’s rho, 0.000 and 0.095, respectively; P 1.0 and
P 0.58, respectively).
Effects of other determinants on the pharmacokinetics of ri-
fampin. In univariate analyses, gender emerged as the only signif-
icant determinant of total and unbound plasma rifampin pharma-
cokinetic parameters. Females were found to be exposed to higher
concentrations of rifampin than males, as indicated by a signifi-
cantly higher total AUC0 –24 (geometric mean, 59.2 versus 48.2 h ·
mg/liter; P  0.02) and higher unbound AUC0 –24 (geometric
mean, 6.2 versus 4.8 h · mg/liter; P  0.02). Total and unbound
Cmax values did not differ significantly between the two groups
(P 0.16 and P 0.22, respectively), as was also the case for Tmax
(P 0.23 and P 0.22, respectively). Univariate analyses did not
show significant correlations for the determinants body weight
and age (data not shown).
As females were overrepresented in the group of patients with
a normal BMI (68%) compared to patients with a BMI below 18.5
kg/m2 (45%) (P 0.20), multiple linear regression analyses were
performed to disentangle the effects of gender and BMI. These
analyses showed that gender was a significant predictor of the
AUC0 –24 of total and protein-unbound rifampin (P  0.02 and
P 0.01, respectively), yet BMI was not (P 0.52 and P 0.35,
respectively). Gender alone explained 15% of the variation (r2) in
both the total and protein-unbound AUC0 –24.
Variability in total and protein-unbound rifampin concen-
trations. To assess the interindividual variability in pharmacoki-
netics, all patients were combined in one group. Both total and
protein-unbound rifampin concentrations showed considerable
variation. The geometric mean total AUC0 –24 for all 36 subjects
was 54.7 h · mg/liter, with a GCV of 26% and a 2.4-fold interindi-
vidual variation in total AUC0 –24, ranging from 32.6 to 88.8 h ·
mg/liter (Table 2 and Fig. 1). The geometric mean unbound
AUC0 –24 amounted to 5.6 h · mg/liter, with a GCV of 32% and a
3.4-fold interindividual variation in unbound AUC0 –24, ranging
from 2.9 to 9.8 h · mg/liter (Table 2 and Fig. 1). Therefore, inter-
patient variabilities in AUC0 –24 for total and unbound rifampin
were considered to be comparable. The same applied for Cmax,
with GCVs of 27% and 30% for total and protein-unbound
rifampin, respectively. Overall, a significant correlation was
found between total and unbound plasma rifampin AUC0 –24
(Spearman’s rho, 0.816; P  0.001) and between Cmax values
(Spearman’s rho, 0.696; P  0.001). The arithmetic mean per-
cent unbound AUC0 –24 was found to be 10.5%, with a CV of
18% and a marked 2-fold interindividual variation in percent
unbound rifampin, ranging from 7.6 to 15.0%.
Figure 2 shows the percent protein-unbound rifampin (free
fraction) at the various sampling time points, and Table 3 sum-
marizes the mean total and unbound rifampin concentrations,
unbound fractions, and interindividual variabilities at the various
sampling time points. The free fraction seemed to be slightly
higher in samples taken later in the pharmacokinetic curve, with
lower total concentrations (Fig. 2 and Table 3).
DISCUSSION
To our knowledge, the present study is the first to obtain both total
and protein-unbound full pharmacokinetic curves of rifampin
during the intensive phase of TB treatment in malnourished and
well-nourished TB patients. The study shows comparable geomet-
ric mean total and protein-unbound AUC0 –24 and Cmax values in
patients who are severely malnourished (BMI of 16.0 kg/m2),
malnourished (BMI of18.5 kg/m2), and well nourished (BMI of
18.5 kg/m2). In addition, there was no significant correlation
between BMI and AUC0 –24 or Cmax for both total and unbound
rifampin plasma levels.
The absence of an effect of malnutrition on rifampin exposure
in this study is in contrast with the results by Polasa et al. (12).
They found that the AUC of a single dose of rifampin was 29%
lower in undernourished (BMI of18 kg/m2) than in well-nour-
FIG 1 Total (Œ) and protein-unbound () concentrations of rifampin (mg/
liter) at various sampling time points postdose. Concentrations are presented
as median interquartile range (IQR).
FIG 2 Percent protein-unbound rifampin (free fraction) at various sampling
time points postdose. Bars represent arithmetic mean SD.
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ished healthy volunteers, with plasma peak concentrations in un-
dernourished persons being 50% of that observed in well-nour-
ished individuals. In the study by Polasa et al., plasma protein
binding was determined with equilibrium dialysis in peak samples
only, and a higher unbound fraction was found in undernour-
ished volunteers. These data suggested that the decrease in total
exposure was at least partly compensated by an increase in the free
fraction. Polasa et al. also showed apparently lower rifampin AUC
and Cmax values in actual undernourished TB patients who had
used rifampin for 4 to 6 months, yet the comparison of steady-
state AUC and Cmax with the single-dose data in healthy volun-
teers is not valid, considering that rifampin decreases its own
exposure upon repeated administration (autoinduction) (30).
Nevertheless, average plasma protein binding for rifampin was
low in these patients as well (42.99%) (12), suggesting a shift in the
equilibrium between total and protein-unbound concentrations.
Indeed we had anticipated that hypoalbuminemia (or a de-
crease in other proteins relevant to binding of drugs) might result
in changes in the total rifampin AUC but not in the protein-un-
bound free AUC in malnourished TB patients, as we considered
that changes in plasma protein binding due to protein deficiency
are very similar to the situation occurring with drug displacement
interactions (24, 25). In this situation, measuring the total con-
centrations would be misrepresentative for the free, pharmacolog-
ical active concentrations, yet in our study, there was even no
trend for a decrease in exposure to total or protein-unbound ri-
fampin in malnourished or severely malnourished versus well-
nourished TB patients. Furthermore, our study did not show a
correlation between BMI and the steady-state protein-unbound
and total rifampin exposure in our cohort. An explanation for our
findings might be that malnourished patients in our study had
higher mean albumin levels than the individuals in the study by
Polasa et al.: 3.8 g/dl (18.5 kg/m2), 3.4 g/dl (18.5 kg/m2), and
3.3 g/dl (16.0 kg/m2) versus 3.6 (18.0 kg/m2) and 2.5 g/dl
(18.0 kg/m2). This indicates that the nutritional status of pa-
tients in our study may be better, suggesting that any effect of
malnutrition mediated through altered binding to albumin was
less likely to occur in our patient population. In contrast, it can
also be argued that serum albumin is a suboptimal indicator of
nutritional status, especially in marasmic populations, as albumin
synthesis can be maintained in such states (32, 33).
Whereas malnutrition did not affect exposure to rifampin, fe-
males showed significantly higher total and unbound AUC0 –24,
also when corrected for BMI. In studies with predominantly Cau-
casian patients, higher serum rifampin concentrations were found
in females, and this could not be explained by differences in body
weight (30, 34). In Indonesian patients, two of our previous stud-
ies found a relationship between gender and rifampin pharmaco-
kinetics (35, 36), but another study did not (11). In African sub-
jects, female patients also showed higher exposures to rifampin
(15). An explanation may be that females generally have a lower
lean body mass than males. Thus, for drugs that are differentially
distributed between water and fat, different drug concentrations
can be found in subjects with the same weight (37). However, it
should be noted here that gender explained only 15% of the vari-
ation (r2) in both the total and protein-unbound AUC0 –24. Thus,
other determinants are probably more important in causing the
(high) variation in rifampin exposures.
With respect to interindividual variability, a marked 2-fold in-
terindividual variation in the unbound rifampin fraction (un-
bound AUC0 –24/total AUC0 –24), between 7.6 and 15.0%, was ob-
served. In addition, the variation in the free fraction at the various
sampling time points was found to be considerably high (Fig. 2),
with CVs ranging from 18 to 26% (Table 3). This large interindi-
vidual variability in the free fraction shows that measurement of
solely total concentrations could be misrepresentative of the ac-
tual exposure. This suggests that protein-unbound rifampin con-
centrations should be considered to evaluate along with total
plasma concentrations for assessment of exposure-response rela-
tionships in clinical studies. The same may apply to individualiza-
tion of rifampin dosing based on plasma concentration measure-
ments (therapeutic drug monitoring) in those settings where this
technique can be used in patient care. In light of this observed high
interindividual variation, the slight increase in the average un-
bound fraction of rifampin found in the lower total concentra-
tions later in the pharmacokinetic curve (Fig. 2) might be less
relevant, also when considering the relatively small number of
patients included in this study. In addition, we cannot exclude that
this small effect is an artifact related to ultrafiltration as a means to
measure protein binding.
In the current study, we measured free rifampin concentra-
tions using ultrafiltration performed at 25°C, as we also do for
other drugs in routine patient care. In ultrafiltration, centrifugal
forces are employed as the driving force for the passage of plasma
water across a filter membrane (38). Besides ultrafiltration, other
methodologies are available to determine plasma protein binding
of drugs, such as ultracentrifugation and equilibrium dialysis. For
rifampin all these techniques have been used. The review by
Kenny and Strates states that in case of equilibrium dialysis, vari-
ous rifampin binding values have been reported based on variable
incubation temperatures, protein concentrations, and dialysis
times (30). However, the specific effect of temperature on the
rifampin-protein complex was not mentioned there or in the lit-
erature. For other drugs, an increase in experimental ultrafiltra-
tion temperatures has been associated with an increase in the free
fraction (39–41), but as far as we know this has not been reported
for rifampin. Indeed, we found that measurement of free rifampin
at 37°C resulted in a small increase in the rifampin-free fraction
TABLE 3 Mean total and unbound rifampin concentrations, unbound
fraction, and interindividual variability at each sampling time point
Time
postdose
(h)
Concn (mg/liter)a
Protein-unbound
fraction (%)b ncProtein unbound Total plasma
0.5 0.3 (67; 0.1–0.8) 2.7 (103; 0.3–9.1) 8.1 (18; 5.6–11.1) 18
1 0.7 (71; 0.08–2.2) 6.5 (102; 0.1–16.6) 9.5 (20; 6.2–14.9) 33
1.5 0.8 (71; 0.08–1.7) 6.8 (93; 0.2–15.8) 10.3 (21; 4.4–13.0) 34
2 0.8 (62; 0.08–1.7) 7.3 (71; 0.8–15.0) 10.3 (18; 6.3–15.6) 35
2.5 0.9 (46; 0.14–1.8) 8.5 (40; 2.1–15.5) 10.2 (20; 6.6–15.0) 36
3 0.8 (31; 0.5–1.6) 8.9 (30; 5.1–15.1) 9.8 (25; 5.3–17.4) 36
4 0.7 (38; 0.4–1.7) 8.7 (33; 4.2–15.0) 8.7 (26; 5.0–17.0) 36
6 0.5 (41; 0.2–1.0) 3.9 (33; 2.1–7.3) 12.4 (21; 8.5–18.4) 36
8 0.3 (48; 0.1–0.6) 2.4 (47; 1.0–6.0) 11.0 (21; 6.4–14.7) 24
12 0.1 (43; 0.06–0.2) 0.5 (68; 0.1–1.5) 13.3 (23; 7.8–20.6) 12
a Values are geometric means (GCV; range); includes concentrations greater than the
limit of quantitation.
b Values are arithmetic means (CV; range); includes concentrations greater than the
limit of quantitation.
c Number of patients for whom a protein-unbound fraction could be calculated based
on quantifiable unbound and total rifampin concentrations.
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(mean change in free fraction, 1.2%; median change, 1.1%;
range,0.7 to3.5%, n 10 rifampin concentrations measured,
P 0.029 [paired t test]) (unpublished data). This effect of tem-
perature on the rifampin free fraction is small and is unlikely to
have affected the findings in our study.
This study has its limitations. First, the number of individuals
included in the malnourished group seems somewhat low with 11
individuals, as a number of 15 individuals per group was calcu-
lated to be required to detect a difference of 25% in rifampin
AUC0 –24. However, with a number of 25 individuals included in
the group with a normal BMI, it can be calculated that the present
study could still detect a 24% difference in the AUC0 –24 of total
rifampin with a significance level of 0.05 and a power of 80%. As a
second limitation, it can be argued that the BMI of the well-nour-
ished group was considerably low (median, 19.6 kg/m2; range,
18.7 to 22.6), resulting in a relatively small difference from the
malnourished group (16.3 kg/m2; 16.1 to 16.4). However, also
when comparing the severely malnourished subgroup with well-
nourished patients and when analyzing BMI as a continuous vari-
able, nutritional status and BMI do not appear to have a major
effect on total and protein-unbound pharmacokinetic parameters
of rifampin. Third, it should be considered that all participants
were Indonesian, and it cannot be excluded that the effect of mal-
nutrition on rifampin pharmacokinetics is different in people
with another racial or genetic background. A final limitation is
that we did not include pharmacogenetic analyses. Pharmacoge-
netic polymorphisms are proposed to be an important factor in
the high variability in rifampin exposure. More specifically, poly-
morphisms of the SLCO1B1 gene have been associated with lower
rifampin exposure (16, 34, 42, 43). To our knowledge, the poten-
tial impact of such polymorphisms in Indonesian TB patients has
not been investigated. According to Niemi et al., the c.463CA
polymorphism, which has been associated with decreased rifam-
pin exposures, is present in only 0 to 3% of the East Asian popu-
lation (44). This indicates that at least this specific polymorphism
is of minor importance in our study population and will not affect
differences in rifampin exposures between malnourished and
well-nourished patients.
To summarize, severely malnourished, malnourished, and
well-nourished Indonesian TB patients showed no clear differ-
ence in total and protein-unbound pharmacokinetic parameters
of rifampin during the intensive phase of TB treatment. Similarly,
BMI and rifampin (total and unbound) pharmacokinetic param-
eters did not show any significant correlation. Significantly higher
plasma concentrations (total and unbound) were found in fe-
males, also when corrected for BMI. Finally, a marked 2-fold in-
terindividual variation in the unbound rifampin fraction was ob-
served. This large interindividual variability in the free fraction of
rifampin shows that measurement of solely total concentrations
could be misrepresentative of the actual exposure, suggesting that
it should be considered to evaluate protein-unbound rifampin
concentrations along with total plasma concentrations when
studying exposure-response relationships for this pivotal TB drug.
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